8039 — TAIFLEX Scientific Co Income Statement
0.000.00%
Last trade - 00:00
- TWD9.83bn
- TWD10.68bn
- TWD8.15bn
- 53
- 40
- 65
- 53
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7,584 | 8,766 | 9,405 | 8,722 | 8,151 |
Cost of Revenue | |||||
Gross Profit | 1,739 | 2,079 | 2,199 | 2,079 | 1,792 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 6,861 | 7,747 | 8,453 | 8,074 | 7,663 |
Operating Profit | 723 | 1,019 | 952 | 648 | 488 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 792 | 966 | 941 | 877 | 482 |
Provision for Income Taxes | |||||
Net Income After Taxes | 618 | 784 | 745 | 692 | 361 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 631 | 773 | 735 | 700 | 423 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 631 | 773 | 736 | 715 | 437 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.16 | 3.64 | 2.99 | 2.87 | 1.73 |
Dividends per Share |